main sites for interactions with the HIV-1 gp120 envelopes following binding to CD4 [reviewed in Zaitseva et al. (8) ] The Nterminus of both CCR5 and CXCR4 are rich in tyrosine residues that are often modified by sulfation in different cells (9) . The sulfated tyrosines were shown to contribute to the binding of CCR5 to MIP1-α, MIP1-β, and HIV-1 gp120/CD4 complexes. In addition, tyrosine-sulfated peptides based on the Nterminus of CCR5 interacted with CD4-bound gp120 and could inhibit viral entry (10, 11) .
Currently, there are three main classes of CCR5-targeting inhibitors under development: CC-chemokine analogues, small molecules, and monoclonal antibodies (8, 12) . Several of these inhibitors have entered clinical trials (12, 13) .
Our group has identified a new CCR5 agonist (C-18) derived from the protozoan parasite Toxoplasma gondii. This protein was identified as an isoform of T. gondii cyclophilin and was shown to signal via murine and human CCR5 and to induce IL-12 secretion from mouse dendritic cells (DC) (14, 15) . In addition, T. gondii cyclophilin C-18, but not a closely related cyclophilin from the apicomplexan protozoan parasite Plasmodium falciparum, bound specifically to human CCR5 and blocked fusion and infection with multiple R5 HIV-1 isolates (16) . In a recent study, we established that the peptidyl prolyl cis-trans isomerase enzymatic activity of T. gondii cyclophilin is not required for its HIV-1 blocking activity in human cells. Furthermore, we identified several amino acids in C-18 critically required for interactions with CCR5 (17) . The current study was aimed at identifying regions in CCR5 that are involved in C-18 binding. This work has identified a critical sequence in the N-terminus of CCR5 that is required for C-18 interaction and anti-HIV activity.
EXPERIMENTAL PROCEDURES
Expression and purification of recombinant C-18 protein-Recombinant C-18 expression and purification steps were described elsewhere (15, 17) . In brief, a plasmid encoding C-18 was transformed into Escherichia coli BL21(DE3)pLys (Invitrogen, Grand Island, NY). Purified inclusion bodies obtained from bacteria induced with isopropyl-1-thio-β-D-galactopyranoside (Invitrogen, Grand Island, NY) for 4 hr were solubilized in 6 M guanidine-HCl. The protein was refolded in 20 mM Tris-HCl, pH 8.0, 150 mM NaCl buffer, dialyzed against 10 mM Tris-HCl, pH 8.0. buffer, and purified on HiPrep 16/10 Q FF column (Amersham Biosciences, Piscataway, NJ), using 10 mM Tris-HCl, pH 8.0, 1 M NaCl for elution. Table 1 lists the sequences of the key peptides used in the study. All peptides were synthesized at the Facility for Biotechnology Resources, CBER on an Applied Biosystems peptide synthesizer model 433 (Foster City, California) by standard 9-fluorenyl methoxycarbonyl chemistry (Fmoc). After cleavage followed by precipitation and washing with methyl tertbutyl ether (MTBE), peptides were purified by reversed-phase high performance liquid chromatography (RP-HPLC) using Walters DeltaPak C-18 column and a linear gradient of 0.1% TFA/water and 0.1% TFA acetonitrile. Fractions containing the desired peptide products were evaporated to remove acetonitrile prior to lyophilization for longterm storage. For peptides with sulfotyrosine, sulfotyrosine was incorporated into the growing peptide chain, on the instrument during synthesis, by using Fmoc-Tyr (SO3Na)-OH (N-a-Fmoc-O-Sulfo-L-Tyrosine sodium salt hydrate) as the building block. The sulfo-tyrosine amino acid, as well as all unmodified amino acids used for this project, was purchased from Anaspec Inc (San Jose, 3 CA). The purified peptides were characterized by mass spectrometry (MALDI-TOF MS).
Peptides-
Peptide ELISA-Peptides/proteins were biotinylated using Maleimide PEO2-Biotin reagent as per manufacturer's instructions (Pierce Biotech, Rockford, IL). The purified C-18 protein (200 ng/well) was coated onto polystyrene wells.
After blocking with Eagle's modified Minimal Essential Medium (EMEM) containing 5% FBS, serial dilutions (100 µl/well) of biotinylated R5 (1-18) peptide (starting concentration of 100 nM) diluted in blocking solution were added to each well, incubated for 1 hr at room temperature (RT), followed by addition of peroxidase conjugated streptavidin. The reaction was quantified using ABTS substrate. Absorbance was measured at 405 nm.
Competition ELISA using synthetic peptidesCompetition of peptides with biotinylated R5 (1-18) peptide for binding to C-18 was performed by peptide ELISA. Fifty microliter (10 µM or 10-fold serial dilutions) of synthetic R5 (1-18) peptide (or its mutant/shorter derivatives) or a control peptide (CXCR4-N-terminus) were added to C-18-coated wells for 30 min at RT. Next, the biotinylated R5 (1-18) peptide (100 nM/50 µl/well) was added for 1 hr at RT. The reaction was developed as described for peptide ELISA. o C in a humidified CO 2 incubator (3 wells per group). Effector cells were added, and syncytium formation was followed for 3 to 4 hours. Linear regression curves were generated and used to calculate the 50% inhibitory dose (ID 50 ). To test the ability of short peptides derived from CCR5 to bind to C-18 and reverse its fusion-inhibiting activity, serially diluted peptides were preincubated with C-18 in microfuge tubes (1:1 ratio) at 37 o C for 60 min. The peptide/C-18 mixtures were then added to PM1 cells (20) in 96-well plates for additional 60 min at 37 o C, after which, the effector cells were added as described above. The C-18-mediated fusion inhibition (in the absence of peptides) was considered as 100% and ranged between 55%-75% inhibition using effector cells expressing JR-FL or Ba-L envelopes.
CCR5 binding assay-
Stably-transfected U87.CD4 cells expressing chimeric CXCR4/CCR5 receptors-The construction of plasmids expressing either wild-type CCR5 or CXCR4/CCR5 chimeric molecules (Designated FC-1, FC-2 and FC4b) and the generation of stably-transfected U87.CD4 cells expressing these chimeric molecules were previously described (21) . In the current study we used U87.CD4 expressing either wt CCR5 or FC-1 (CXCR4 Pro42/Pro35 CCR5), FC-2 (CXCR4 Asp74/Ile67 CCR5), and FC-4b (CXCR4 Ile185/Cys178 CCR5) cells. Surface expression of the WT or chimeric CXCR4/CCR5 receptors in the U87.CD4 transfectants was monitored by flow cytometry using either mAb 2D7 (PharMingen), which recognize an epitope in the ECL-2 of CCR5, or mAb 5/5B5, which recognize the CXCR4 N-terminal peptide (amino acids 2-16), as previously described (2, 21) . The four cell lines expressed comparable levels of WT CCR5 or CXCR4/CCR5 chimeric receptors (Fig. 1 ).
Viral infectivity assay-JC.6 (HeLa-CD4 cells expressing wild-type CCR5) and R5d18.2 (HeLa-CD4 cells expressing CCR5 that lacks N-terminal amino acids 2-19) and HIV-1 variant JR-CSF18.2ad D2 [adapted to grow on CCR5 (delta 18)]-HeLa-CD4 cells were previously described (22)(Platt et al., submitted). The Hela-CD4 derivatives were grown in low glucose DMEM supplemented with 10% FBS and penicillin/streptomycin (DMEM/FBS medium). No selection drug was added. Twenty-four hr before infection, cells were plated in flat bottom 96-well plates (2x10 3 cells per well, in 200 µl DMEM/FBS medium. Prior to infection, the medium was removed and cells were treated for 20 min with serum-free DMEM (low glucose) medium containing DEAE Dextran (8 µg/ml), followed by washing with serum-free DMEM. C-18 was added to wells containing cells for 2 hr at 37 o C, after which, JR-CSF(18.2ad) virus was added at 0.75 x 10 3 focus forming units/well. After 24 hr incubation of cells, C-18, and virus at 37 o C in a CO 2 incubator, the cells were washed extensively (to remove unbound virus and inhibitor), and fresh DMEM/FBS medium was added to all wells. The plates were cultured for 2 weeks. Supernatants were removed daily, and the cultures were supplemented with fresh medium. Viral production was determined by measuring p24 in culture supernatants using a commercial enzyme-linked immunosorbent assay kit (PerkinElmer Life Sciences, Boston, MA).
RESULTS

C-18 mediated fusion-inhibition requires the N-terminus of CCR5-
In order to delineate the regions within CCR5 that contribute to C-18 binding, we made use of a panel of U87.CD4 cells expressing chimeric CXCR4/CCR5 (or wt CCR5) receptors. All four stablytransfected cell lines expressed similar levels of co-receptor ( Fig. 1 ) and were previously shown to support infection of Ba-L (21) and several primary isolates (23) . In a fusion assay, all four cell lines fused with 12E1 effector cells expressing the Ba-L envelope at similar levels ( Fig. 2 legend) . Fusion of cells expressing wt CCR5 was effectively blocked by C-18, by the CCR5-agonist MIP1-β, and by mAb 2D7, which targets a conformationalsensitive epitope in CCR5 ECL-2 ( Fig.2) . In contrast, cells expressing the FC-1, FC-2, and FC-4b chimeric CXCR4/CCR5 receptors, which have the entire N-terminus plus increasing amounts of sequences from CXCR4, fused with JR-FL Env-expressing cells, but were not blocked by either C-18 or MIP1-β. Mab 2D7 blocked fusion of cells expressing wild-type CCR5, FC-1, and FC-2 chimeric co-receptors. In contrast, fusion with FC-4b-expressing cells was not inhibited by mAb 2D7, most likely because the key residues 171-KE-172 at the base of CCR5 ECL-2, which are required for 2D7 binding, were replaced by CXCR4 amino acids in this chimeric receptor (21, 24, 25) (Fig. 2) . These results suggested that the CCR5 N-terminus is required for C-18 binding.
Peptides derived from the CCR5 N-terminus can reverse C-18-mediated fusion inhibition-
We next used a panel of synthetic peptides derived from the N-terminus and the extracellular loop-2 (ECL-2) of CCR5 (Table  1) to further investigate the C-18 contact sites. All the peptides used in the current study had no inhibitory or enhancing effects on the fusion assay when added alone at the highest concentration used (100 µg/ml) (data not shown). Serially diluted peptides were preincubated with C-18 (at 20 µg/ml; 1.1 µM) for 1 hr at 37 o C. The solutions, containing C-18 mixed with CCR5-derived peptides, were then added to 96-wells containing PM1 cells for additional 1 hr at 37 o C. 12E1 cells expressing JR-FL envelope were added to the same wells (at a 1:1 ratio), and syncytia were scored after 3 hrs. Based on the maximal inhibition seen by C-18 alone, it was possible to calculate the peptide concentrations required for 50% reduction of C-18-mediated fusion inhibition. As can be seen in figure 3 , panel A, a peptide containing the complete Nterminus sequence (31 amino acids) could reverse the inhibitory activity of C-18 at ID 50 of 23.1 µg/ml (85.2 µM). Control peptide derived from CXCR4 N-terminus did not reverse the inhibitory activity of C-18 (Fig. 3 , panel E). The CCR5 N(1-31) was also able to block the binding of Since the N-terminal 31 amino acids may acquire secondary structure in solution, and this region of CCR5 was shown to contain multiple distinct binding sites for different agonists, we next tested shorter sequences from the CCR5 N-terminus. The last 16 amino acids gave very minimal C-18 blocking (data not shown). On the other hand, a peptide containing only the first 18 amino acids from the N-terminus of CCR5 [CCR5 N(1-18)] was 150 fold more active than the 31 amino acid peptide in reversing the fusion inhibition of C-18 (Fig. 3, panel B) . A scrambled peptide, CCR5 N(1-18)SCR, had no activity and did not reverse the inhibitory activity of C-18 ( Fig. 3, panel F) . The observed increased activity of N(1-18) peptide compared with N(1-31) peptide suggests that the shorter peptide has a better fit for C-18, while in the context of the 31 amino acid CCR5 Nterminus peptide a significant amount of folding may occur in solution resulting in masking or steric hindrance for C-18 binding. The EC-II derived peptide did not significantly block the fusion-inhibitory activity of C-18 (data not shown). To further map the critical amino acids within CCR5 N(1-18) required for C-18 activity, we examined the ability of two shorter peptides from this region to compete out C-18 fusion inhibition. Surprisingly, the first 9 residues of CCR5 N-terminus [CCR5 N(1-9)] had no competitive activity (not shown), while the peptide containing residues 10-18 was very active with ID 50 of 0.14 µM, identical to CCR5 N(1-18) (Fig. 3, panels B and C) .
It was previously reported that CCR5 N-terminus contains several tyrosine residues that are sulfated, and this post-translational modification is required for interaction with both chemokines and gp120/CD4 complexes (9, 26 ). Thus, we tested peptide CCR5 N(1-18) containing two sulfated tyrosines (Y 10 S ,Y 14 S ). Our data revealed that the sulfated peptide was able to reduce the activity of C-18 with almost identical ID 50 to that of the unsulfated CCR5 N(1-18) peptide (Fig. 3, panel D) .
The N(1-18) and N(10-18) peptides were also tested for their ability to block the binding of 125 I-C-18 to CCR5-expressing CEM cells (Fig. 5) . As was demonstrated in the fusion assay, peptides encompassing Nterminal amino acids 1-18 or 10-18 were significantly more effective than the 31 amino acid peptide in competing C-18 binding to CCR5 + CEM cells. Even at 1:1 molar ratios significant displacement of 125 I-C-18 was observed with the shorter N-terminus peptides (Fig. 5) . As expected, no inhibition of C-18 binding was seen with a control (1-18, scrambled) peptide (SCR).
C-18 does not block HIV-1 infection of cells expressing N-terminal-truncated CCR5 coreceptors-
To further address the contribution of the N-terminus of CCR5 to C-18 binding and fusion-inhibitory activity, we tested two recently generated HeLa.CD4 cell derivatives expressing either wild-type CCR5 (JC.6) or a CCR5 with N-terminal truncation of amino acids 2-19 (R5d18.2). In a fusion assay with effector cells expressing the JR-FL envelope, both target cells could fuse well. This assay is very sensitive since the effector cells are infected overnight with vaccinia expressing HIV envelopes, resulting in high envelopeexpression levels. It was clear that, while mAb 2D7 could block fusion of cells expressing either wild-type or truncated CCR5, C-18 completely lost its inhibitory activity against cells expressing the N-terminal truncated CCR5 molecules (Fig. 6) . The same cells were also used in an infection assay using a variant of JR-CSF that was adapted to grow on R5d18.2 cells. It was reported that this viral variant does interact with the N-terminus of CCR5, even though it no longer requires this interaction for fusion and infection (most likely due to increased binding avidity to other CCR5 domains) (Platt et al., submitted) . In our study, the JR-CSF18.2adD2 variant replicated two-fold better on the JC.6 cells expressing wild-type CCR5 compared with cells expressing truncated CCR5. C-18 reduced infection of JC.6 cells by 75%. In contrast, the same viral variant was resistant to C-18 inhibition when grown on the R5d18.2 cells (Table 2) . These data further suggested that the first 19 N-terminal amino acid sequence of CCR5 contain crucial residues required for C-18 binding and anti-viral activity.
Alanine scanning to determine key CCR5 contact residues-To further map the amino acids within CCR5 N(1-18) critical for C-18 activity, we next conducted alanine-scanning mutagenesis, replacing each of the amino acids in the shorter peptide with alanine (Table 3) . Peptides with alanine replacement of either Y 10 , D 11 or E 18 were fully active. On the other hand, alanine substitutions in each of the remaining amino acids (12) (13) (14) (15) (16) (17) in this peptide significantly reduced the ability of the peptide to reverse the fusion-inhibitory activity of C-18. The largest loss of activity was observed with I 12 A, Y 14 A, T 16 A, and S 17 A mutant peptides (Table 3) .
These peptides were also tested in a direct binding ELISA assay. Wells coated with C-18 were reacted with biotinylated CCR5(1-18) peptide or biotinylated scrambled peptide containing the same 18 amino acids. As seen in Fig. 7 , using streptavidin-HRP for the detection of bound peptide, it was possible to measure the binding of biotinylated CCR5 N(1-18) peptide to C-18 in a dose-dependent manner. No association of the scrambled peptide with C-18 was detected. In the peptide competition ELISA, when the CCR5 N(10-18) peptides containing alanine substitutions were added to the C-18 coated plates at 1, 10, or 100-fold molar excess, they competed with binding of the biotinylated CCR5 N(1-18) peptide in a dose-dependent fashion, and in good agreement with the results from the fusion assay, again showing the importance of CCR5 residues 12-17 for C-18 binding (compare Fig. 8 with Table 3 ). The location of the key residues in the N-terminus that were shown to be involved in C-18 binding is circled in the CCR5 model in Fig. 9 [according to Siciliano et al (27) ].
DISCUSSION
The protozoan parasite Toxoplasma gondii cyclophilin produces a protein, cyclophilin-18 (C-18), that can bind to the chemokine receptor CCR5, apparently as a result of a molecular mimicry with the native ligands. In mice, the C-18/CCR5 interaction is involved in the upregulation of IL-12 production, an important mediator of host resistance to this pathogen (15, 28) . While many other pathogens acquired the ability to express chemokine-like proteins or chemokine receptor analogues (29, 30) , to our knowledge, only T. gondii expresses a cyclophilin isomer that binds to CCR5 from several diverse species. In the previous study, we have identified structural determinants within C-18 required for its antiviral activity (17) . In this counterpart study, we have defined the critical residues within human CCR5 sequence required for binding and HIV inhibitory activity of C-18. Our experiments identified a short sequence in the N-terminus of CCR5, amino acids 12-17, as a crucial docking site for C-18. Based on the alignment of CCR5 sequences in mouse, human, and Rhesus macaques (Fig. 10) , there are 5 conserved residues between human and mouse CCR5 in this region, including two tyrosines at positions 10 and 14, which help explain C-18 binding to cell surface CCR5 from various species. The homology with Rhesus CCR5 is much higher, with only a single asparagine to aspartic acid change in amino acid 13. This high level of homology in this region, would suggest that Rhesus CCR5 should support C-18 binding. Experiments are in progress and preliminary data demonstrates C-18 inhibition of SIV Env-mediated fusion with activated Rhesus PBMC consistent with this prediction.
HIV-1 gp120 also evolved to utilize CCR5 as a major co-receptor for viral entry.
Extensive work identified a key role for the Nterminus and ECL-2 in gp120 binding (reviewed in (8)). Importantly, sulfated synthetic peptides derived from the Nterminus of CCR5 were shown to bind to gp120/CD4 complexes in ELISA (31) . Furthermore, binding of the natural CCR5 ligands MIP1-α, MIP1-β, and RANTES, involves similar but not completely overlapping sites in CCR5. In addition to the N-terminus and ECL-2, these β-chemokines were demonstrated to interact with the transmembrane (TM) region of CCR5 (25, (32) (33) (34) . Thus, a common feature of the binding to CCR5, is docking to the less conformationaly constrained N-terminus, followed by additional interactions with either the EC loops or the TM regions. In our earlier study we demonstrated that MIP1-β and an R5 gp120 (Ba-L) can compete with iodinated C-18 for binding to CEM.NKR.CCR5 cells, suggesting that the binding sites are at least partially overlapping (16) .
Of interest is the role played by sulfated tyrosines in the N-terminus of CCR5 in C-18 binding/activity. It was previously demonstrated that sulfation of tyrosine residues in position 3, 10, 14, and 15 significantly contribute to the efficiency of gp120 binding and increased viral entry (9, 11, 26) . The exact contribution of the sulfate moieties to gp120 binding has not been deciphered, but it was postulated to add a polar, highly charged surface that interacts with positively charged residues in the gp120 V3 or in the co-receptor binding β-sheet. Unregulated signaling, induction of proinflammatory cytokines, as well as receptor down-regulation and/or interference with key biological functions, must be addressed. In the case of C-18, we previously established that it does not induce down-regulation of surface CCR5 (16) . In our more recent study of the structural determinants of the anti-HIV activity of C-18, it was also found that several mutations designed to completely destroy the enzymatic activity of C-18, did not reduce its HIV-1 blocking activity. Importantly, the same mutations did abolish the ability of C-18 to induce IL-12 from mouse DC (17) . Thus, these mutants are likely to have a higher safety profile for future human trials. These and other C-18 derivatives are currently being tested in vitro for their anti-HIV and anti-SIV activities.
Several studies demonstrated that early depletion of CD4 + CCR5 + T cells in gutassociated tissues occurs early and at all stages of HIV-1 infection, even in the face of highly active anti-retroviral therapies. It was suggested that anti-viral therapies may be augmented by new interventions aimed at blocking chemokine receptor-mediated fusion targeting the mucosal immune system where the vast majority of CD4 + CCR5
+ T cells reside. Further function/structure studies on the interaction of C-18 with CCR5 could be applied towards the synthesis of either more potent C-18 derivative or a C-18 mimic (peptides or small molecules) that will be of potential use as a microbicidal agent, either alone or in combination with other CCR5-and HIV-blocking compounds (35) (36) (37) (38) 39) . We are grateful to Keith Peden, Carol Weiss, and Paolo Lusso for their helpful suggestions during the preparation of this manuscript. We thank Jody Manischewitz for her technical support. This study was supported by NIH Intramural AIDS Targeted Antiviral Program (IATAP). Liselotte Antonsson was supported by the Network of Inflammation Research funded by the Swedish Foundation Strategic Research. .CD4.FC-2, and U87.CD4.FC-4b were treated with C-18 (20 µg/ml), MIP1-β (10 µg/ml), or mAb 2D7 (10 µg/ml) for 60 min at 37 o C, followed by the addition of 12E1 cells expressing JR-FL envelope. Syncytia were scored after 3 hr. Control syncytia (no inhibitor present) were: 230 + 12; 232 + 13; 276 + 4; and 192 + 15 for the four cell lines respectively. All groups were run in triplicate and the standard deviations were between 10-15% of the means. The experiment shown is representative of three performed. Fig. 3 . Blocking of C-18 fusion-inhibitory activity by pre-incubation with CCR5 derived soluble peptides. C-18 was used at 20 µg/ml (1.1 µM). The % inhibition by C-18 alone ranged between 55%-75%. Serially diluted peptides were incubated with C-18 in 0.5 ml microfuge tubes for 1 hr at 37 o C. The mixtures were added to wells containing PM1 cells for additional 1 hr at 37 o C, after which effector cells expressing JR-FL (or Ba-L) envelope were added (E/T ration of 1:1). Syncytia were scored after 3 hrs. The peptide concentration required to reduce the fusioninhibitory activity of C-18 by 50% was based on at least three separate determinations for each peptide. No fusion inhibition was observed adding the peptides alone under the same conditions (not shown). CCR5 N(1-18) peptide binds to C-18. ELISA plates were coated with C-18 and were reacted with serially diluted biotinylated CCR5 N(1-18) peptide or with biotinylated scrambled peptide [CCR5 N(1-18)SCR] containing the same amino acids, followed by addition of peroxidase conjugated Streptavidin. The reactions were quantified using ABTS substrate. Absorbance was measured at 405 nm. Fig. 8. Competition of C-18 binding to biotinylated CCR5 N(1-18) peptide with shorter Nterminus peptides containing single amino acid-alanine substitutions. C-18 coated plates were incubated with synthetic peptides derived from CCR5 N(1-18), CCR5 N(1-9), CCR5 N(10-18), and a series of CCR5 N(10-18) with alanine substitutions. All peptides were at 10, 1, or 0.1 µM. After 30 min incubation at RT, the biotinylated CCR5 N(1-18) peptide was added at 100 nM (competitor: binding peptide ratio of 100:1, 10:1, or 1:1). After 1 hr at RT the plates were washed and developed as in Fig. 7 . Fig. 9 . Localization of the main C-18 binding site in the N-terminus of CCR5. The thread model of human CCR5 according to Siciliano et al (27) . The highlighted amino acids are those that differ between human and Rhesus CCR5 proteins. Serially diluted peptides were incubated with C-18 in 0.5 ml microfuge tubes for 1 hr at 37 o C. The mixtures were added to wells containing PM1 cells for additional 1 hr at 37 o C, after which effector cells expressing JR-FL envelope were added (E/T ration of 1:1). Syncytia were scored after 3 hrs. The peptide concentration required to reduce the fusion-inhibitory activity of C-18 by 50% was based on at least three separate determinations for each peptide (See also Fig. 3) . In all experiments the control syncytia (in absence of C-18) ranged between 300-400 syncytia per well with 10% SD. The % inhibition by C-18 alone ranged between 65%-75%. No fusion inhibition was observed on adding the peptides alone under the same conditions (data not shown). 
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